This is the issue where the correct answer is that the number does not exist. That is worth saying at length, because the absence is doing a great deal of work in this market and almost nobody names it.
The Yellow Card scheme run by the Medicines and Healthcare products Regulatory Agency accepts reports of suspected adverse drug reactions and of adverse incidents involving medical devices. It covers both sides of the injectable aesthetics picture: toxins as medicines, fillers as devices.
What it does not do is produce a denominator. A voluntary reporting scheme tells you what was reported. It cannot tell you what proportion of procedures resulted in harm, because nobody counts procedures.
ObservedThe Yellow Card scheme accepts reports relating to both medicines and medical devices, and the reporting route is open to patients as well as to professionals.AnalysisWithout a denominator, a rise in reports is uninterpretable. It could be more harm, more awareness, or more procedures. All three explanations fit the same data.Report anyway. The scheme is the only national signal detection mechanism that exists here, and its weakness is partly a function of how few people in this sector use it.
Complication content is the most searched and least well served category in aesthetics. Patients search for symptoms after treatment, often urgently, and they search in ordinary language.
Clinics avoid publishing on it because it is commercially uncomfortable, which leaves the space to forums, social posts and a small number of clinical sources. The result is an information environment in which the most anxious searcher gets the least institutional answer.
AnalysisThe commercial disincentive is real and it is short sighted. A patient searching complication symptoms at eleven at night is not being acquired by anyone. They are being reassured or frightened by whoever published.SpeculationClinical explanatory content about complications may be among the most citable material available in this category, because the alternatives are anecdotal. We would expect institutional sources to dominate here and largely they do.Publishing what can go wrong, what it looks like, and what to do about it is the clearest available demonstration that a clinic understands its own risk. It is also, awkwardly, good marketing.
The clinical bodies in this sector publish guidance on the recognition and management of complications, and that guidance is the most clinically substantive material the voluntary layer produces.
What no body has produced is a registry. A voluntary complications registry has been discussed in this sector for years. Building one requires participants to report events that damage them commercially, with no statutory requirement and no protection, which is a collective action problem with an obvious solution nobody can impose.
ObservedNo comprehensive national complications registry for non surgical cosmetic procedures currently operates in the UK.AnalysisVoluntary registries succeed where reporting is protected, professionally expected and low cost. None of those three conditions currently holds in this sector.A registry will not appear voluntarily. If it arrives, it arrives attached to a licensing scheme, which is one of the stronger arguments for such a scheme and is rarely the argument made for it.
Patients now ask about specific named complications rather than about risk generally, and they ask about vascular occlusion by name.
That is a substantial change. It requires the practitioner to discuss a serious, time critical complication in a consultation that was designed to be reassuring, and it exposes any clinic that does not hold the means to manage it. The question behind the question is whether the practitioner could act if it happened while the patient was in the chair.
AnalysisThe vocabulary arrived from complication accounts circulating publicly. It is a case of patients becoming more clinically literate than the marketing they are shown.ObservedRecognition and immediate management of vascular complications is addressed in the clinical guidance published by professional bodies in this field.Answer it directly: what the complication is, how it presents, what the practitioner does immediately, what is held on site, and where the patient goes if escalation is needed. A clinic that cannot answer the last two parts has answered the question.
Any specific complication rate. Percentages circulate widely in this sector and almost none can be traced to a UK denominator. Where a figure comes from a published clinical study, it describes that study's population and technique, not the market.
"Complication free." Describes a record, not a property, and an unaudited record at that. "Fully reversible." Depends on the product, the complication and the timing, and it is stated far more often than it is true.
ObservedWhere complication frequencies appear in the peer reviewed literature they are specific to the studied population, product and technique. Generalising them to a national market is not a valid inference.We will not print a complication rate. Not because the literature contains nothing, but because a number lifted from a study and presented as a market rate is a fabrication with a citation attached, and that is worse than saying we do not know.
Complication management is a cost centre with no revenue line, and that is the root of most bad behaviour around it.
Managing a complication properly takes unscheduled practitioner time, may require product held for that purpose, and often involves treating a patient for free while they are unhappy. A clinic that has not budgeted for it has an incentive to minimise, delay or dispute, and every one of those responses converts a clinical event into a reputational one.
AnalysisThe costliest complication is the one managed reluctantly. Time to response is the variable that determines both the clinical and the commercial outcome, and it is set by whether the clinic has decided in advance who pays.SpeculationClinics that publish a complications policy with a stated financial position on correction may be doing something more commercially sensible than it looks, because it removes the negotiation at the worst possible moment.Decide in advance who pays for what, write it down, and give it to the patient before treatment. The policy costs nothing to write and it is the single most useful document in the business.
The absence of data will eventually be filled by something, and the likeliest candidate is not a registry but litigation and media reporting, both of which produce case level detail without any denominator.
That produces a predictable dynamic: vivid individual accounts, no base rate, and a public conversation that oscillates between alarm and dismissal because there is nothing stable to anchor it.
SpeculationExpect the public understanding of risk in this sector to remain volatile as long as there is no denominator. Volatility in perceived risk is itself a commercial risk for every operator.AnalysisThe sector's interest and the public interest align here, which is unusual. Both would benefit from a count. Neither can produce one unilaterally.If you want the argument to become boring, produce the number. Until someone does, this stays an argument about anecdotes, and anecdotes favour whoever tells them best.